レーバー遺伝性視神経症(レーバー視神経萎縮)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0965
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:115
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Leber’s Hereditary Optic Neuropathy – Pipeline Review, H1 2020, provides an overview of the Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline landscape.

Leber’s hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person’s teens or twenties, rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Leber’s Hereditary Optic Neuropathy – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 1, 7, 2 and 2 respectively. Similarly, the Universities portfolio in Phase III and Phase I stages comprises 1 and 1 molecules, respectively.

Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Leber’s Hereditary Optic Neuropathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leber’s Hereditary Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leber’s Hereditary Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (Ophthalmology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leber’s Hereditary Optic Neuropathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Overview
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Therapeutics Development
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Therapeutics Assessment
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Companies Involved in Therapeutics Development
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drug Profiles
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Dormant Projects
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Alkeus Pharmaceuticals Inc, H1 2020
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Antoxis Ltd, H1 2020
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Biovista Inc, H1 2020
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Fortify Therapeutics Inc, H1 2020
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by GenSight Biologics SA, H1 2020
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Pipeline by Ixchel Pharma LLC, H1 2020
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Dormant Projects, H1 2020

【掲載企業】

Alkeus Pharmaceuticals Inc
Antoxis Ltd
Biovista Inc
Fortify Therapeutics Inc
GenSight Biologics SA
Ixchel Pharma LLC
Khondrion BV
Metro International Biotech LLC
Mitobridge Inc
Mitotech SA
Nanna Therapeutics Ltd
Neuroptika Inc
Santhera Pharmaceuticals Holding AG
Stealth BioTherapeutics Corp

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[レーバー遺伝性視神経症(レーバー視神経萎縮)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆